Society for Radiation Oncology Administrators

News

     
Forgot Login
Join SROA

Now exclusively online, access the latest SROA Radiation Oncology News for Administrators publication by clicking on this link.

2011 SROA Press Releases

Awards Program

Racial Disparities in Cancer Survival Persist for Specific Types of Breast, Ovarian and Prostate Cancers

July 20, 2009

Despite uniform staging, treatment and follow-up, disparities in cancer mortality for African Americans held true in a recent study of patients diagnosed with pre- and post-menopausal breast and advanced ovarian and prostate carcinomas.

The Southwest Oncology Group (SWOG) studied the outcomes of 19,457 adult patients diagnosed with cancer to determine whether racial survival disparities persist when clinical, demographic and treatment variables are consistent. The study by Kathy S. Albain, et al, “Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients,” was published in the July 13, 2009, Journal of the National Cancer Institute.

The researchers looked for associations between race and overall survival by grouping results from 35 SWOG phase III clinical trials based on diseases with similar histology and stage. They then controlled for prognostic, treatment and socioeconomic factors.

After adjusting for prognostic factors, the authors found that race was associated with increased mortality from early-stage pre-menopausal breast cancer, early-stage post-menopausal breast cancer, advanced-stage ovarian cancer and advanced-stage prostate cancer. However, African Americans with lung cancer, colon cancer, lymphoma, leukemia or myeloma in the study had a similar survival rate to other study participants.

African Americans in the study faced a 68 percent vs. 77 percent, not reached, overall survival rate for early stage and pre-menopausal breast cancer; 52 percent (10.2 years) vs. 62 percent (13.5 years) for early-stage, post-menopausal breast cancer; 13 percent (1.3 years) vs. 17 percent (2.3 years) for advanced ovarian cancer; and 6 percent (2.2 years) vs. 9 percent (2.7 years) for advanced prostate cancer.

“Unrecognized interactions of tumor biological, hormonal and/or inherited host factors may be contributing to differential survival outcomes by race in sex-specific malignancies,” the authors concluded.

Print this page © 2006-2012 SROA | All rights reserved. 5272 River Rd., Suite 630 Bethesda, MD 20816   -   Phone: 301-718-6510
SROA@paimgmt.com   -   Privacy Policy   -   Terms of Use